Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-01-28

FDA Approved: DIVALPROEX SODIUM — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for divalproex sodium submitted by BluePoint Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DIVALPROEX SODIUM (divalproex sodium)

Snippet

SUPPL AP for DIVALPROEX SODIUM (DIVALPROEX SODIUM)